Earnings call transcript: Dentsply Sirona Q2 2025 sees earnings beat, stock rises

Dentsply Sirona reported Q2 2025 adjusted EPS of $0.52 and revenue of $936 million, both surpassing analyst forecasts, which drove an 8.26% pre-market stock increase. Despite these beats, global sales declined 5% year-over-year, notably impacted by continued softness in the U.S. market and an increased annual tariff headwind now estimated at $80 million. New CEO Dan Scavilla outlined a strategic focus on restoring U.S. growth, enhancing operational efficiency, and making targeted investments to unlock value, while the company maintained its full-year 2025 sales and adjusted EPS guidance.

Analysis

Dentsply Sirona (XRAY) reported a mixed operational picture for Q2 2025, exceeding consensus on earnings and revenue but revealing persistent top-line pressures. The company posted an adjusted EPS of $0.52, a 7% year-over-year increase, on revenue of $936 million, which marked a 5% year-over-year decline. A key driver of profitability was a 360-basis-point expansion in the adjusted EBITDA margin to 21%, reflecting successful cost-reduction programs and the impact from suspending its BITE product. However, this operational efficiency masks significant underlying challenges, most notably an 18% sales decline in the U.S. market, driven by softness in the Connected Technology Solutions and implant segments. The earnings call was the first for new CEO Dan Scavilla, who emphasized a strategy focused on execution, restoring U.S. growth, and enhancing customer focus, while maintaining the company's full-year 2025 guidance. This outlook now incorporates a newly increased annualized tariff headwind of approximately $80 million, up from a $50 million estimate, which is expected to begin weighing on margins in the third quarter.

Key Decisions for Investors

• Investors should view XRAY as a turnaround story contingent on the new leadership's ability to execute a recovery in the challenged U.S. market, as near-term EPS beats are being supported by cost controls rather than organic growth.
• It is critical to monitor U.S. sales figures and performance in the Connected Technology Solutions (CTS) and implant segments in the upcoming quarters as the primary proof points of the new strategy's effectiveness.
• Be cautious of the significant updated headwind from an $80 million annualized tariff impact, which will begin to pressure margins in the second half of 2025 and makes the maintained full-year guidance highly dependent on cost mitigation.
• Considering the stock remains near its 52-week low despite the post-earnings jump and is noted as potentially undervalued, investors confident in the new management may see a favorable entry point for a long-term position.